- Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024
- Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
- Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD
- Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024
- Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
- Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
- Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
- Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
- Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
- Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024
More ▼
Key statistics
On Monday, Aligos Therapeutics Inc (ALGS:NAQ) closed at 0.81, 50.33% above the 52 week low of 0.5388 set on Oct 24, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.8302 |
---|---|
High | 0.8304 |
Low | 0.80 |
Bid | 0.79 |
Offer | 0.82 |
Previous close | 0.8101 |
Average volume | 206.05k |
---|---|
Shares outstanding | 75.67m |
Free float | 57.26m |
P/E (TTM) | -- |
Market cap | 61.30m USD |
EPS (TTM) | -1.82 USD |
Data delayed at least 15 minutes, as of May 06 2024 21:00 BST.
More ▼